VERSANT VENTURE CAPITAL VI, L.P. sold 9.1% of their position (157.90K shares) of MONTE ROSA THERAPEUTICS, INC. on the open market
Open‑market sale worth $1.49M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−89.99K
Price / share
$9.66
Trade value
$869.24K
% of position
Common Stock
Shares
−1.02M
Price / share
—
Trade value
—
% of position
Common Stock
Shares
+20.40K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
−20.40K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
+17.59K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
−17.59K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
−366.59K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
+5.50K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
−5.50K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
+5.45K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
−5.45K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
−52.30K
Price / share
$9.08
Trade value
$475.01K
% of position
Common Stock
Shares
−15.60K
Price / share
$9.41
Trade value
$146.79K
% of position
Net shares
−1.54M
Net value
-$1.49M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 10/28/2024 | S · Sale | −89.99K | $9.66 | $869.24K | 4.3% | 2.10M | 2.01M |
| Common Stock Direct | 10/28/2024 | J · J | −1.02M | — | — | 20.0% | 5.10M | 4.08M |
| Common Stock Indirect | 10/28/2024 | J · J | +20.40K | — | — | New position | 0.00 | 20.40K |
| Common Stock Indirect | 10/28/2024 | J · J | −20.40K | — | — | New position | 20.40K | 0.00 |
| Common Stock Indirect | 10/28/2024 | J · J | +17.59K | — | — | New position | 0.00 | 17.59K |
| Common Stock Indirect | 10/28/2024 | J · J | −17.59K | — | — | New position | 17.59K | 0.00 |
| Common Stock Indirect | 10/28/2024 | J · J | −366.59K | — | — | 18.3% | 2.01M | 1.64M |
| Common Stock Indirect | 10/28/2024 | J · J | +5.50K | — | — | New position | 0.00 | 5.50K |
| Common Stock Indirect | 10/28/2024 | J · J | −5.50K | — | — | New position | 5.50K | 0.00 |
| Common Stock Indirect | 10/28/2024 | J · J | +5.45K | — | — | New position | 0.00 | 5.45K |
| Common Stock Indirect | 10/28/2024 | J · J | −5.45K | — | — | New position | 5.45K | 0.00 |
| Common Stock Indirect | 10/29/2024 | S · Sale | −52.30K | $9.08 | $475.01K | 3.2% | 1.64M | 1.59M |
| Common Stock Indirect | 10/29/2024 | S · Sale | −15.60K | $9.41 | $146.79K | 1.0% | 1.59M | 1.57M |
| Total | −1.54M | -$1.49M | ||||||